Search
Calcium lactate
go.drugbank.com/drugs/DB13231ApprovedVet approvedCalcium lactate is also found in daily dietary supplements as a source of calcium. It is also available in various hydrate forms, where calcium lactate pentahydrate is the most common. … It is prepared commercially by the neutralization of lactic acid with calcium carbonate or calcium hydroxide.
Mixtures: Min-tran TabDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Compounds used in a research, industrial, or household settingATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Talniflumate
go.drugbank.com/drugs/DB09295InvestigationalTalniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405]. … In addition, it is used in inflammatory conditions such as rheumatoid arthritis.
AT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalA prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month.
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Gefapixant
go.drugbank.com/drugs/DB15097ApprovedIt received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Pegilodecakin
go.drugbank.com/drugs/DB15162InvestigationalPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small
Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED